| abstract |
The invention relates to quinazoline derivatives of formula (I) wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C¿1-3?alkyl, C1-3alkoxy, C1-3alkylthio, or -NR?5R6¿ (wherein R?5 and R6¿, which may be the same or different, each represents hydrogen or C¿1-3?alkyl); R?2¿ represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C¿1-3?alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X?1¿ represents -O-, -CH¿2?-, -S-, -SO-, -SO2-, -NR?7¿CO-, -CONR8-, -SO¿2?NR?9-, -NR10SO¿2- or -NR11- (wherein R?7, R8, R9, R10 and R11¿ each independently represents hydrogen, C¿1-3?alkyl or C1-3alkoxyC2-3alkyl); R?4¿ represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group selected from alkyl and a 5 or 6 membered saturated carbocyclic or heterocyclic group, and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis. |